PeopleBio, Inc. (KOSDAQ:304840)
South Korea · Delayed Price · Currency is KRW 1,490.00
+29.00 (1.98%)
At close: Apr 24, 2026
PeopleBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,851 | 2,531 | 4,453 | 4,445 | 577.08 |
Other Revenue | 0 | -0 | - | - | 0 |
| 2,851 | 2,531 | 4,453 | 4,445 | 577.08 | |
Revenue Growth (YoY) | 12.64% | -43.17% | 0.18% | 670.22% | 13.63% |
Cost of Revenue | 3,327 | 2,100 | 3,077 | 3,115 | 1,365 |
Gross Profit | -476.51 | 430.9 | 1,376 | 1,330 | -787.66 |
Selling, General & Admin | 5,359 | 5,968 | 10,370 | 8,692 | 3,728 |
Research & Development | 1,750 | 2,288 | 5,160 | 3,390 | 2,119 |
Amortization of Goodwill & Intangibles | 96.46 | 27.54 | 358.16 | 380.16 | 177.95 |
Other Operating Expenses | 215.76 | 250.15 | 277.62 | 176.91 | 130.17 |
Operating Expenses | 11,720 | 9,116 | 16,623 | 13,027 | 6,448 |
Operating Income | -12,197 | -8,685 | -15,248 | -11,697 | -7,236 |
Interest Expense | -2,700 | -943.28 | -2,399 | -2,979 | -1,134 |
Interest & Investment Income | 272.06 | 236.52 | 376.99 | 533.49 | 98.51 |
Earnings From Equity Investments | -901.6 | -947.05 | -934.89 | -835.96 | -380.5 |
Currency Exchange Gain (Loss) | -14.89 | 2.54 | -34.87 | 15.67 | -1.9 |
Other Non Operating Income (Expenses) | 2,768 | 1,586 | 2,277 | -58.18 | 3,706 |
EBT Excluding Unusual Items | -12,773 | -8,751 | -15,962 | -15,020 | -4,947 |
Gain (Loss) on Sale of Investments | 418.76 | -433.8 | -395.43 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 17.65 | 5.17 |
Other Unusual Items | -191.36 | 20.68 | -1,025 | - | - |
Pretax Income | -12,545 | -9,164 | -17,382 | -15,003 | -4,942 |
Earnings From Continuing Operations | -12,545 | -9,164 | -17,382 | -15,003 | -4,942 |
Earnings From Discontinued Operations | -4,393 | -3,009 | - | - | - |
Net Income to Company | -16,939 | -12,173 | -17,382 | -15,003 | -4,942 |
Minority Interest in Earnings | 1,225 | 1,260 | 1,348 | 699.7 | 244.85 |
Net Income | -15,714 | -10,913 | -16,035 | -14,303 | -4,697 |
Net Income to Common | -15,714 | -10,913 | -16,035 | -14,303 | -4,697 |
Shares Outstanding (Basic) | 22 | 22 | 17 | 15 | 14 |
Shares Outstanding (Diluted) | 22 | 22 | 17 | 15 | 16 |
Shares Change (YoY) | 0.11% | 31.16% | 13.30% | -8.80% | 32.17% |
EPS (Basic) | -722.00 | -502.00 | -967.45 | -977.75 | -340.35 |
EPS (Diluted) | -722.00 | -502.00 | -967.45 | -978.00 | -457.08 |
Free Cash Flow | -5,396 | -10,990 | -17,001 | -15,242 | -8,188 |
Free Cash Flow Per Share | -247.93 | -505.52 | -1025.76 | -1041.91 | -510.46 |
Gross Margin | -16.72% | 17.03% | 30.90% | 29.92% | -136.49% |
Operating Margin | -427.87% | -343.21% | -342.42% | -263.16% | -1253.81% |
Profit Margin | -551.26% | -431.25% | -360.10% | -321.79% | -813.94% |
Free Cash Flow Margin | -189.30% | -434.27% | -381.80% | -342.91% | -1418.84% |
EBITDA | -10,450 | -6,993 | -13,683 | -10,415 | -6,501 |
EBITDA Margin | - | -276.35% | - | -234.32% | - |
D&A For EBITDA | 1,747 | 1,692 | 1,565 | 1,282 | 734.08 |
EBIT | -12,197 | -8,685 | -15,248 | -11,697 | -7,236 |
EBIT Margin | - | - | - | -263.16% | - |
Advertising Expenses | 174.78 | 181.61 | 2,905 | 2,879 | 223.74 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.